This phase I trial studies the best dose and side effect of volitinib in treating participants with Medulloblastoma, High-Grade Glioma or Diffuse Intrinsic Pontine Glioma that have come or does not respond to treatment. Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PBTC-049: A Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma
Inclusion Criteria:
Exclusion Criteria:
For more information contact:
Cincinnati Children’s Hospital Medical Center
Division of Hematology / Oncology
3333 Burnet Ave., Cincinnati OH 45229-3039
Phone: 513-636-2799
Email: cancer@cchmc.org